NCT00006327

Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand

A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,500 (planned)
• Sponsor: VaxGen · Industry
• Sex: All
• Age: 20 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.

Detailed description

Volunteers are immunized and followed for a minimum of 2 years. Any volunteer that becomes infected with HIV-1 is followed every 4 months post infection for up to 36 months. Behavior effects associated with study participation are assessed.

Conditions

• HIV Infections
• HIV Seronegativity

Interventions

Type	Name	Description
BIOLOGICAL	MN rgp120/HIV-1 and A244 rgp120/HIV-1

Timeline

• Start date: 1999-03-01
• Completion: 2000-08-01
• First posted: 2001-08-31
• Last updated: 2005-06-24

Locations

1 site across 1 country: Thailand